Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18292536rdf:typepubmed:Citationlld:pubmed
pubmed-article:18292536lifeskim:mentionsumls-concept:C0020964lld:lifeskim
pubmed-article:18292536lifeskim:mentionsumls-concept:C2936626lld:lifeskim
pubmed-article:18292536lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:18292536pubmed:issue5lld:pubmed
pubmed-article:18292536pubmed:dateCreated2008-2-22lld:pubmed
pubmed-article:18292536pubmed:abstractTextAlterations to the tumor microenvironment following localized irradiation may influence the effectiveness of subsequent immunotherapy. The objective of this study was to determine how IFN-gamma influences the inflammatory response within this dynamic environment following radiotherapy. B16/OVA melanoma cells were implanted into C57BL/6 (wild-type (WT)) and IFN-gamma-deficient (IFN-gamma-/-) mice. Seven days after implantation, mice received 15 Gy of localized tumor irradiation and were assessed 7 days later. Irradiation up-regulated the expression of VCAM-1 on the vasculature of tumors grown in WT but not in IFN-gamma-/- mice. Levels of the IFN-gamma-inducible chemokines MIG and IFN-gamma-inducible protein 10 were decreased in irradiated tumors from IFN-gamma-/- mice compared with WT. In addition to inducing molecular cues necessary for T cell infiltration, surface MHC class I expression is also up-regulated in response to IFN-gamma produced after irradiation. The role of IFN-gamma signaling in tumor cells on class I expression was tested using B16/OVA cells engineered to overexpress a dominant negative mutant IFN-gamma receptor (B16/OVA/DNM). Following implantation and treatment, expression of surface class I on tumor cells in vivo was increased in B16/OVA, but not in B16/OVA/DNM tumors, suggesting IFN-gamma acts directly on tumor cells to induce class I up-regulation. These increases in MHC class I expression correlated with greater levels of activated STAT1. Thus, IFN-gamma is instrumental in creating a tumor microenvironment conducive for T cell infiltration and tumor cell target recognition.lld:pubmed
pubmed-article:18292536pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18292536pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18292536pubmed:languageenglld:pubmed
pubmed-article:18292536pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18292536pubmed:citationSubsetAIMlld:pubmed
pubmed-article:18292536pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18292536pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18292536pubmed:statusMEDLINElld:pubmed
pubmed-article:18292536pubmed:monthMarlld:pubmed
pubmed-article:18292536pubmed:issn0022-1767lld:pubmed
pubmed-article:18292536pubmed:authorpubmed-author:LordEdith MEMlld:pubmed
pubmed-article:18292536pubmed:authorpubmed-author:FrelingerJohn...lld:pubmed
pubmed-article:18292536pubmed:authorpubmed-author:GerberScott...lld:pubmed
pubmed-article:18292536pubmed:authorpubmed-author:MoranJames...lld:pubmed
pubmed-article:18292536pubmed:authorpubmed-author:LugadeAmit...lld:pubmed
pubmed-article:18292536pubmed:authorpubmed-author:SorensenEliza...lld:pubmed
pubmed-article:18292536pubmed:issnTypePrintlld:pubmed
pubmed-article:18292536pubmed:day1lld:pubmed
pubmed-article:18292536pubmed:volume180lld:pubmed
pubmed-article:18292536pubmed:ownerNLMlld:pubmed
pubmed-article:18292536pubmed:authorsCompleteYlld:pubmed
pubmed-article:18292536pubmed:pagination3132-9lld:pubmed
pubmed-article:18292536pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:meshHeadingpubmed-meshheading:18292536...lld:pubmed
pubmed-article:18292536pubmed:year2008lld:pubmed
pubmed-article:18292536pubmed:articleTitleRadiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.lld:pubmed
pubmed-article:18292536pubmed:affiliationDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.lld:pubmed
pubmed-article:18292536pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18292536pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:18292536pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18292536lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18292536lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18292536lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18292536lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18292536lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18292536lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18292536lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18292536lld:pubmed